Vistagen Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
OrbiMed Advisors LLC and OrbiMed Capital LLC have filed an amendment reporting zero shares beneficially owned in Vistagen Therapeutics, Inc.
NASDAQ
TCG Crossover entities have updated their Schedule 13G filing, reporting beneficial ownership of Vistagen Therapeutics' common stock, primarily through exercisable warrants.
NASDAQ
Janus Henderson Group plc reports 0% beneficial ownership in Vistagen Therapeutics, Inc., signaling a complete divestment of its previous stake.
NASDAQ
StemPoint Capital LP, along with its general partner and Michelle Ross, reported a 1.5% beneficial ownership stake in Vistagen Therapeutics, Inc., primarily through warrants.
NASDAQ
Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a beneficial ownership of 4.71% in VistaGen Therapeutics, Inc. as of December 31, 2025.
NASDAQ
The Vanguard Group has filed an amended Schedule 13G, reporting a 4.62% beneficial ownership in Vistagen Therapeutics Inc. following an internal realignment.
NASDAQ
OrbiMed Advisors LLC and OrbiMed Capital LLC have jointly reported a combined beneficial ownership of 9.97% of Vistagen Therapeutics, Inc.'s common stock.
NASDAQ
SCHEDULE 13G/A: Nantahala Capital Boosts Vistagen Stake to 9.99%
Nantahala Capital Management, LLC and its managing members reported a 9.99% beneficial ownership stake in Vistagen Therapeutics, Inc. as of September 30, 2025.
NASDAQ
Great Point Partners, LLC and its principals have disclosed a 6.28% beneficial ownership stake in Vistagen Therapeutics, Inc., primarily through warrants.
NASDAQ
The Vanguard Group reported a 5.5% beneficial ownership stake in Vistagen Therapeutics Inc., holding 1,687,735 common shares as of September 30, 2025.
NASDAQ
Janus Henderson Group plc and its affiliate have reported a significant passive stake of 13.6% in Vistagen Therapeutics, Inc. common stock.
NASDAQ
Great Point Partners, LLC and its principals, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, reported a combined beneficial ownership of 6.59% in Vistagen Therapeutics, Inc. common stock.
NASDAQ
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly reported a beneficial ownership of 6.65% in Vistagen Therapeutics, Inc., totaling 2,055,834 shares.
NASDAQ
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay and Ms. Lillian Nordahl, have jointly filed an amendment to their Schedule 13G, disclosing a combined beneficial ownership of 6.88% in Vistagen Therapeutics, Inc.
NASDAQ
SCHEDULE 13G/A: Biotechnology Value Fund Entities Disclose Significant Stake in Vistagen Therapeutics, Holding Nearly 10% of Shares
A group of investment entities managed by Biotechnology Value Fund, including Mark N. Lampert, have disclosed a combined beneficial ownership of 9.97% in Vistagen Therapeutics, Inc., primarily through common stock and exercisable warrants.
NASDAQ
StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have jointly disclosed a beneficial ownership of 8.2% in Vistagen Therapeutics, Inc., as of December 31, 2024.